Novo Nordisk stock: cooling off before earnings
Novo Nordisk stock falls 3.5% as sellers take control, earnings just ahead
Novo Nordisk stock: cooling off before earnings
Our view last week
Novo Nordisk slips 3.1% this week with sellers in the majority, but the weekly MACD has just turned positive and money flow stays firm: signs of a slowdown, not a reversal of the underlying trend. The stock is holding inside the double bottom in the 43 area that already produced a 6% rebound. Novo Nordisk shares remain a buy still in profit, and the weekly technical analysis shows a picture that's still intact, just less decisive.
This week's summary
Among pharma stocks, Novo Nordisk stock closed the week down 3.5%, with sellers firmly in control: 89% of volume turned to selling and buyer dominance suddenly collapsed. Money flow still stays positive, though cooling, while the weekly RSI slides toward neutral territory. After last week's slowdown, technical analysis shows further fading momentum, with the August 5 earnings report now close at hand.
IQS Phase
46
ordinary
Signal Strength
70
high · wide & volatile
Sizing
FULL
Ranking
#20 / 120
US stocks in progress
Trade P&L %
+7.29%
from signal to date, no stop loss
Rank position
ranks 20th among the 120 Longs already running for US stocks in our ranking, with a signal strength of 70 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein positive regime
Performanceweekly -0.01% · monthly +1.89%
NVO belongs to the health care sector (reference ETF XLV). The sector is classified in positive regime according to our weekly reading.
restricted Platinum content